Bevacizumab clinically refers to bevacizumab injection, and the main cancers that can be treated at present are metastatic colorectal cancer and advanced, metastatic or recurrent non-small cell lung cancer.
1. Metastatic colorectal cancer: Bevacizumab combined with fluoropyrimidine-based chemotherapy is suitable for the treatment of patients with metastatic colorectal cancer.
2. Advanced, metastatic or recurrent non-small cell lung cancer: Bevacizumab in combination with platinum-based chemotherapy is indicated for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer.
3. Recurrent glioblastoma: Bevacizumab is used for the treatment of adult patients with recurrent glioblastoma.
4. Hepatocellular carcinoma: Combined with atilizumab for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic systemic therapy.
5. Epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: Bevacizumab combined with carboplatin and paclitaxel is used as the first-line treatment for patients with stage III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer after primary surgical resection.
6. Cervical cancer: Bevacizumab combined with paclitaxel and cisplatin or paclitaxel and topotecan is used for the treatment of patients with persistent, recurrent or metastatic cervical cancer.
It should be noted that the use of drugs should be used under the guidance of a doctor, do not take on their own, so as not to delay the disease